Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Citi
Johnson and Johnson
Accenture
Cerilliant
Teva
Fuji
Chubb
Daiichi Sankyo

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,770,623

« Back to Dashboard

Which drugs does patent 6,770,623 protect, and when does it expire?

Patent 6,770,623 protects FORTEO and is included in one NDA.

This patent has forty-two patent family members in thirty-two countries.
Summary for Patent: 6,770,623
Title: Stabilized teriparatide solutions
Abstract:A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
Inventor(s): Chang; Chin-Ming (Fishers, IN), Havel; Henry A. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/555,476
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Composition; Use; Dosage form;

Drugs Protected by US Patent 6,770,623

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y A METHOD OF TREATING OSTEOPOROSIS ➤ Sign Up
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Sign Up ➤ Sign Up Y FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,770,623

PCT Information
PCT FiledDecember 08, 1998PCT Application Number:PCT/US98/26043
PCT Publication Date:June 17, 1999PCT Publication Number: WO99/29337

Non-Orange Book US Patents Family Members for Patent 6,770,623

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,144,861 Stabilized teriparatide solutions ➤ Sign Up
7,550,434 Stabilized teriparatide solutions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Johnson and Johnson
Boehringer Ingelheim
US Department of Justice
Colorcon
Farmers Insurance
US Army
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.